Quick Answer
SkinHealth Systems Inc. reported Research And Development Expense of $5.63 million for the year ending 2025.
- SkinHealth Systems Inc. showed a decrease of -10.6% in Research And Development Expense from 2024 to 2025.
- This data is from SkinHealth Systems Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $597.0 thousand | Q3 2020: $577.0 thousand | Q1 2021: $1.45 million | Q2 2021: $2.99 million | Q3 2021: $1.88 million | Q1 2022: $2.23 million | Q2 2022: $2.60 million | Q3 2022: $2.17 million | Q1 2023: $2.34 million | Q2 2023: $2.88 million | Q3 2023: $1.84 million | Q1 2024: $2.81 million | Q2 2024: $1.16 million | Q3 2024: $1.11 million | Q1 2025: $998.0 thousand | Q2 2025: $1.25 million | Q3 2025: $1.70 million.
- Over the full 7 years of available data (2019 to 2025), SkinHealth Systems Inc.'s Research And Development Expense has grown by 22.0%.
- Historical annual values: Fiscal year 2025: $5.63 million | Fiscal year 2024: $6.30 million | Fiscal year 2023: $10.10 million | Fiscal year 2022: $8.44 million | Fiscal year 2021: $8.20 million | Fiscal year 2020: $3.41 million | Fiscal year 2019: $4.61 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: